-
公开(公告)号：US20240317866A1
公开(公告)日：2024-09-26
申请号：US18216026
申请日：2023-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Joshua Curtin , Roland Knoblauch , Meena Thayu
CPC classification number: C07K16/2863 , A61K9/0019 , A61K45/06 , A61P35/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/565
Abstract: The present disclosure provides methods of treating gastric or esophageal cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
-
2.发明公开公开(公告)号：US20230174677A1
公开(公告)日：2023-06-08
申请号：US17988176
申请日：2022-11-16
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch
CPC classification number: C07K16/468 , A61P35/00
Abstract: The present invention relates to methods of treating lung cancer using an approved drug product comprising amivantamab. Also described are drug products containing amivantamab, and methods of selling or offering for sale a drug product comprising amivantamab.
-
公开(公告)号：US20220395573A1
公开(公告)日：2022-12-15
申请号：US17725755
申请日：2022-04-21
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch , Satyen Torne
IPC: A61K39/395 , C07K16/28 , A61K47/42 , A61K47/12 , A61K47/26 , A61K47/20 , A61K47/18 , A61P35/00 , A61K9/00
Abstract: Provided herein are stable aqueous pharmaceutical compositions comprising high concentration formulations of a bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and methods of preparing the same. Also provided herein are methods of treating cancer in a subject in need thereof by subcutaneously administering to the subject the stable aqueous pharmaceutical compositions as disclosed herein.
-
公开(公告)号：US20230183360A1
公开(公告)日：2023-06-15
申请号：US18077318
申请日：2022-12-08
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch
CPC classification number: C07K16/2863 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: The present invention relates to methods of treating colorectal cancer (CRC), such as metastatic colorectal cancer (mCRC), in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody (e.g., a bispecific antibody) to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met).
-
公开(公告)号：US20220064306A1
公开(公告)日：2022-03-03
申请号：US17411158
申请日：2021-08-25
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch , Sheri Moores
Abstract: The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations.
-
Patent Agency Ranking
公开(公告)号：US20210253717A1
公开(公告)日：2021-08-19
申请号：US17174386
申请日：2021-02-12
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch , Sylvie Laquerre , Sheri Moores
Abstract: The present invention relates to treatment of subjects having a cancer that is positive for c-Met exon 14 skipping mutations.
-
公开(公告)号：US12215160B2
公开(公告)日：2025-02-04
申请号：US17174386
申请日：2021-02-12
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch , Sylvie Laquerre , Sheri Moores
Abstract: The present invention relates to treatment of subjects having a cancer that is positive for c-Met exon 14 skipping mutations.
-
公开(公告)号：US20240109969A1
公开(公告)日：2024-04-04
申请号：US18222093
申请日：2023-07-14
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch
IPC: C07K16/28 , A61K31/282 , A61K31/519 , A61K31/5377 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2863 , A61K31/282 , A61K31/519 , A61K31/5377 , A61K39/39558 , A61P35/00 , A61K2039/545 , C07K2317/31
Abstract: Provided are methods of treating an epidermal growth factor receptor (EGFR)-expressing or hepatocyte growth factor receptor (c-Met)-expressing cancer in a subject in need thereof. The methods comprise administering to the subject a therapy comprising an isolated bispecific anti-EGFR/c-Met antibody, wherein the administration comprises a dose of about 1400-2100 mg, administered once per a 21-day cycle.
-
公开(公告)号：US20240368310A1
公开(公告)日：2024-11-07
申请号：US18613945
申请日：2024-03-22
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch
Abstract: The present invention relates to methods of treating lung cancer using an approved drug product comprising amivantamab. Also described are drug products containing amivantamab, and methods of selling or offering for sale a drug product comprising amivantamab.
-
公开(公告)号：US20240034813A1
公开(公告)日：2024-02-01
申请号：US18201516
申请日：2023-05-24
Applicant: Janssen Biotech, Inc.
Inventor： Roland Knoblauch , Satyen Torne
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/31 , C07K2317/565
Abstract: Provided herein are stable aqueous pharmaceutical compositions comprising high concentration formulations of a bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and methods of preparing the same. Also provided herein are methods of treating cancer in a subject in need thereof by subcutaneously administering to the subject the stable aqueous pharmaceutical compositions as disclosed herein.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.014 seconds)
